

## Augtyro (repotrectinib) Prior Authorization Request Form Caterpillar Prescription Drug Benefit



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_

MEMBER'S FIRST NAME: \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	·
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	
MALE FEMALE HEIGHT (IN/CM):	WEIGHT (LB/KG): ALLERGIES:

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi\_disclosure\_authorization.pdf</u>

## PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
<b>REQUESTOR</b> (if different than prescriber):	OFFICE CONTACT PERSON:		

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAP	Y INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page

© 2017 – 2018, Magellan Rx Management. All Rights Reserved. Magellan Rx Management – Commercial Clients. Revision Date: 5.1.2024 CAT009





## Augtyro (repotrectinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:				
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO			
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
<ul> <li>Non-small cell lung cancer (NSCLC)</li> <li>Other diagnosis:</li> </ul>	ICD-10 Code(s):				
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINI	ICAL INFORMATION TO SUPPORT A			
Is patient going to be using drug in a	clinical trial? 🗆 Yes 🗆 No				
Does patient have a diagnosis of locally advanced, or metastatic non-small cell lung cancer(NSCLC)/solid tumor (including primary CNS tumors) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement? • Yes • No Please submit documentation. Does patient have an ECOG score of 0-1? • Yes • No Please submit documentation. Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.					
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.					
Prescriber Signature or Electronic I.D.	Verification:	Date:			
you are not the intended recipient, you are her	ompanying this transmission contain confidential eby notified that any disclosure, copying, distribut have received this information in error, please ese documents.	tion, or action taken in re liance on the contents			
FAX THIS FORM TO: 800-424-7640					
MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn:CP-4201 P.O.Box 64811					
St. Paul, MN 55164-0811					
Phone: 877-228-7909					

© 2017 – 2018, Magellan Rx Management. All Rights Reserved. Magellan Rx Management – Commercial Clients. Revision Date: 5.1.2024 CAT009



